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Venous thromboembolism in multiple myeloma is associated
with increased mortality
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Abstract
Background: In multiple myeloma, venous thromboembolism (VTE) is common, and
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treatments for myeloma, such as lenalidomide, increase the risk of thrombosis while
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Objectives: To determine the association between VTE and survival in multiple my-
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improving survival. The association between VTE and survival is not well known.
eloma (MM) while adjusting for known confounders that affect risk of thrombosis
and survival, including patient characteristics and treatment in a retrospective cohort
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was created to assess the association between VTE and mortality using Cox propor-

5

Funding information
National Heart, Lung, and Blood Institute,
Grant/Award Number: K12 HL087107-05
Handling Editor: Dr Neil Zakai

Patients/Methods: A cohort of patients with newly diagnosed MM treated within
Veterans Health Administration between September 1, 1999, and June 30, 2014,
tional hazards regression modeling while accounting for known prognostic factors
and treatments.
Results: The cohort comprised 4446 patients with myeloma, including 2837 patients
diagnosed after lenalidomide approval in July 2006. VTE occurred in 327 (7.4%) patients within 1 year and occurred at a median of 77 days (interquartile range, 37-153)
after starting therapy for MM. In all patients, VTE was associated with increased
mortality at 6 months (adjusted hazard ratio [aHR], 1.67; 95% confidence interval
[CI], 1.18-2.37). Patients in the post-lenalidomide cohort with VTE had an increased
mortality at both 6 months (aHR, 2.31; 95% CI, 1.52-3.51) and 12 months (aHR, 1.66;
95% CI, 1.19-2.33) after treatment initiation.
Discussion: This study shows that VTE during the first 6-12 months of therapy is
associated with increased mortality in patients with MM. Studies evaluating thromboprophylaxis in patients at high risk of thrombosis are needed.
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Essentials
• Deep vein thrombosis (DVT) in multiple myeloma is common and associated with therapy.
• Retrospective analysis of patient from 1999-2014 treated for myeloma within the Veterans Health Administration.
• DVT associated with death at 6 and 12 months when adjusting for patient factors and therapy.
• Risk of DVT was highest in the first 3 months of treatment.

1 | INTRODUCTION

we excluded patients who received a hematopoietic cell transplant
(HCT) within 4 months of treatment initiation, as these patients likely

Patients with multiple myeloma (MM) have increased risk of venous

received treatment outside of the VHA system (Figure 1). Before co-

thromboembolism (VTE) that is 7- to 9-fold higher compared to pa-

hort creation, the Saint Louis VHA Medical Center and Washington

tients without MM.1,2 VTE is associated with increased morbidity3

University School of Medicine institutional review boards approved

4

and is a leading cause of death in patients with cancer however, evi-

this study.

dence of the association of VTE with mortality in MM is limited and
conflicting. Two single-center studies in patients receiving aggressive MM-directed therapy demonstrated no overall association of
VTE on survival.

5,6

2.2 | Measurements and covariates

Conversely, a large population-based study found

inferior survival in patients with MM and VTE; however, that study

We obtained ICD-9-Clinical Modification (CM) codes, Pharmacy

had a limited ability to adjust for confounders, such as treatments or

Benefits Management (PBM) records, and laboratory data using the

comorbid conditions.7 Further understanding of the effect of VTE

VA Informatics and Computing Infrastructure platform. Records

on survival in MM could inform strategies for VTE prevention.

from PBM included dates of administration of all medications, in-

MM treatment guidelines recommend use of thromboprophy-

cluding MM-directed therapy. We identified autologous HCT by

laxis in patients with MM after risk stratification.8-10 Two recent

the presence of at least two ICD-9 codes or by the administration

randomized controlled trials demonstrated a decrease in the risk of

of high-dose melphalan. We defined MM therapy as administration

VTE with thromboprophylaxis in ambulatory patients with cancer

of melphalan, thalidomide, lenalidomide, bortezomib, doxorubicin,

identified as high risk for VTE.11,12 However, a significant number of

cyclophosphamide, vincristine, or etoposide and cisplatin within

patients with MM and high risk of thrombosis do not receive throm-

6 months of diagnosis, which were recommended first-line treat-

boprophylaxis.13 In clinical trials, rates of VTE in MM remain >10%

ments in national guidelines during the study period.17 The number

during the first 6 months of treatment despite protocols for throm-

of therapies in the initial treatment regimen was equal to the sum

boprophylaxis.14 The development of two clinical risk assessment

of all MM therapies administered within 1 month of first treatment

scores for VTE in MM, SAVED15 and IMPEDE VTE16, could improve
identification of patients with MM at highest risk of VTE.
Considering prior conflicting evidence, an improved understanding of the impact of VTE on survival in MM could provide rationale

Newly diagnosed multiple myeloma treated
within the VHA from 1999-2014 (n = 4,805)

for the benefit of thromboprophylaxis in patients with MM using risk
assessment scores. Therefore, we used a large, nationwide cohort of

Weight or Height Unavailable (n = 201)

US veterans to understand the impact of VTE on survival in patients
with MM.

2 | METHODS
2.1 | Study population
We identified patients with newly diagnosed MM from September 1,
1999, to June 30, 2014, within the Veterans Health Administration

Laboratory Data Unavailable (n = 59)

Transplant within 120 days of Chemotherapy Start
(n = 38)

VTE after MM Diagnosis and before Chemotherapy
Start (n = 61)

Full Analytic Cohort (n = 4,446)

(VHA) Central Cancer Registry using International Classification
of Diseases (ICD)-03 codes 9732/3 and received treatment within
the VHA. To remove patients suspected of having monoclonal gammopathy of undetermined significance, solitary plasmacytoma, or
smoldering myeloma, we excluded patients who did not receive
MM-directed therapy within 6 months of diagnosis. Additionally,

Treatment after July 1,2007: postIenalidomide cohort (n = 2,837)
F I G U R E 1 Flow diagram showing selection process of
analytic cohorts. MM, multiple myeloma; VHA, Veterans Health
Administration; VTE, venous thromboembolism
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initiation and included both dexamethasone or prednisone as

post-lenalidomide cohort was assessed at 6 and 12 months, while

therapies.

adjusting for the same potential confounders as listed above. We

Baseline demographics collected included sex, race, and age at
the time of MM diagnosis. We calculated body mass index (BMI)

used SAS 9.4 (SAS Inc, Cary, NC, USA) for all analyses. All P values
were two-tailed, with P < .05 determined as significant.

using height and weight within 1 month of diagnosis. Laboratory
data included albumin, creatinine, and hemoglobin at the time closest to but within 2 months of MM diagnosis and before initiation

3 | RESULTS

of therapy. We calculated creatinine clearance (CrCL) using the
Cockcroft-Gault formula. Using at least two ICD-9-CM codes within

A total of 4446 patients were included. Mean age was 68.4 years,

12 months before MM diagnosis, we calculated the Romano adap-

and the median year of diagnosis of myeloma was 2008 (Table 1).

tation of the Charlson Comorbidity Index to account for comorbid-

Consistent with the veteran population, 97.8% of patients were male

ities present at diagnosis.18 We identified date of death using the

and 29.8% were Black. Patients were predominantly treated with

VA Vital Status File, which combines the death dates from multi-

two agents (61.5%) while 20.0% were treated with a single agent, and

ple sources including the VA Beneficiary Identification and Records

18.4% received three or more agents. Of the cohort, 2837 received a

Locator Subsystem Death File, the Social Security Administration

diagnosis of MM after July 1, 2006 (post-lenalidomide cohort).

Death Master File, the Medicare Vital Status File, and the Medical

Within 1 year of initiation of therapy, 327 (7.4%) patients devel-

SAS Inpatient Dataset. Survival was measured as the time from date

oped VTE, and 185 (6.5%) developed VTE within 6 months. Incidence

of MM diagnosis to date of death.

of thrombosis was highest in the first 3 months after chemother-

We identified VTE within 12 months of chemotherapy initiation

apy start date, with median time from chemotherapy start to VTE

using an algorithm that includes ICD-9 codes for VTE (from both

77 days (interquartile range, 37-153 days). Cumulative incidence of

inpatient and outpatient encounters) as well as treatment for VTE,

VTE at 12 months in the full cohort was 8.4%, and in the cohort

19

We confirmed all incident

treated after July 2006 it was 7.4% (Figure 2). Most of the events

cases of VTE identified by the algorithm with manual chart abstrac-

as previously validated for this cohort.

were lower-extremity DVTs, but 92 patients had a PE (Table 2).

tion. We defined a VTE event as present if there was imaging confir-

Patients with VTE had a higher BMI (P < .001) and were more likely

mation of an upper proximal extremity or lower-extremity proximal

to receive multidrug treatment regimens (P = .01).

or distal VTE and/or pulmonary embolism (PE). Imaging evaluated

In our cohort, 821 (18.5%) patients died within 6 months after

for diagnosis included ultrasonography, computed tomography,

start of therapy, and 1208 of 4446 patients (27.2%) died within

ventilation/perfusion imaging assessed as high probability for VTE,

1 year. Median survival of the overall cohort was 32.5 months

or clinician documentation of imaging-proven VTE from an outside

(35.4 months in the post-lenalidomide cohort). When restricting the

institution.

survival analysis to patients treated with lenalidomide or thalidomide at the start of therapy, median survival was 41.7 months.

2.3 | Statistical analyses

After adjusting for potential confounders, VTE was associated
with an increased mortality at 6 months after initiation of therapy
(adjusted hazard ratio [aHR], 1.67; 95% confidence interval [CI],

Demographic and clinical characteristics were compared between

1.18-2.37) in the full cohort, with a trend toward increased risk at

patients with and without VTE within 12 months of treatment ini-

12 months (aHR, 1.22; 95% CI, 0.93-1.60) (Table 3). Patient char-

tiation using chi-square, Student’s t, or Cochran-Mantel-Haenszel

acteristics significantly associated with increased risk of mortality

tests as appropriate. The association between VTE and survival at 6

included BMI of <18.5, older age, non-Black race, higher Charlson

and 12 months was assessed using Cox proportional hazards regres-

Comorbidity Index, CrCL < 30 mL/min, and albumin of ≤3 g/dL at

sion modeling while adjusting for potential confounding variables.

diagnosis. Overweight and obesity, Black race, initial therapy with

Confounders included age at diagnosis; Charlson Comorbidity Index;

lenalidomide or thalidomide, and treatment with higher number of

20

21

Black race ; BMI ; treatment with thalidomide, lenalidomide, or

therapies in the first regimen were significantly associated with de-

bortezomib; receipt of HCT; anemia (hemoglobin < 10 g/dL); impaired

creased mortality.

CrCL (Cockcroft-Gault formula < 30 mL/min); albumin ≤ 3 g/dL; year

In the post-lenalidomide cohort, VTE was associated with in-

of diagnosis; and number of therapies in the first regimen. VTE was

creased mortality at 6 months after start of chemotherapy (aHR,

included as a time-varying covariate to account for immortal time bias.

2.31; 95% CI, 1.52-3.51) when adjusting for potential confounders

To understand the impact of VTE on survival in a modern era of

(Table 4). This risk of increased mortality remained significant at

management, a subcohort of patients diagnosed with MM between

12 months (aHR, 1.67; 95% CI, 1.19-2.33). Patient characteristics sig-

July 1, 2006, and June 30, 2014, was created to account for the pe-

nificantly associated with increased mortality included a BMI < 18.5,

riod after first US Food and Drug Administration (FDA) approval of

older age, higher Charlson Comorbidity Index, CrCL < 30 mL/min,

lenalidomide for MM (post-lenalidomide cohort). Using a Cox pro-

and albumin of ≤3 g/dL at diagnosis. Factors associated with de-

portional hazards regression modeling with VTE as a time-varying

creased mortality included more recent year of diagnosis such that

exposure, the association between VTE and survival in MM in the

patients treated closer to 2014 had decreased mortality compared
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Demographics and clinical characteristics of US veterans treated for MM
US veterans diagnosed with MM between
9/1/1999 and 6/30/2014 (full cohort,
n = 4446)

US veterans diagnosed with MM
between 7/1/2006 and 6/30/2014 (postlenalidomide cohort, n = 2837)

VTE n = 327
(7.4%)

VTE n = 185
(6.5%)

No VTE n = 2652
(97.5%)

P value

67.6

68.5

.28a

96.2 (178)

97.8 (2594)

.19b

No VTE n = 4119
(92.6%)

P value

Mean age, y

67.3

68.5

.051

Male, n (%)

96.9 (317)

98.0 (4035)

.22b

Mean Charlson-Romano Comorbidity Index

2.9

3.4

a

.005

a

3.3

.13a

3.7

.65b

Race
White/Other

71.3 (233)

70.1 (2886)

Black

28.7 (944)

29.9 (1233)

.59b
71.4 (132)

69.5 (1842)

28.6 (53)

30.5 (810)

.009c

BMI (%)

.02c

0.6 (2)

2.5 (104)

0.5 (1)

2.3 (60)

18.5-<25

27.8 (91)

31.1 (1281)

25.4 (47)

30.4 (805)

25-<30

38.5 (126)

38.7 (1593)

38.4 (71)

37.8 (1003)

≥30

33.0 (108)

27.7 (1141)

35.7 (66)

30.0 (784)

4.9 (16)

2.3 (93)

<18.5

VTE before MM (%, n)

.003b

5.4 (10)

2.9 (77)

.06b

b

37.3 (69)

40.2 (1065)

.44b

18.9 (35)

22.1(586)

.31b

Anemia (%)

39.8 (130)

40.6 (1671)

.77

CrCl < 30 mL/min (%)

20.2 (66)

22.7(933)

.33b

Albumin (mean)
Transplant in 1 y after diagnosis (%, n)

3.3
14.1 (46)

3.3

.66

8.9 (366)

3.3

.002

b

b

Melphalan in 1 y after diagnosis (%, n)

25.1 (82)

25.7 (1181)

.17

Lenalidomide use in 1 y after diagnosis (%, n)

22.6(74)

22.7 (933)

.99b

.81

12.4 (23)

10.0 (266)

.30 b

20.0 (37)

19.2 (508)

.78b

38.4(71)

34.6 (918)

.30 b

Thalidomide use in 1 y after diagnosis (%, n)

43.7 (143)

30.1 (1239)

<.001

30.8 (57)

24.6 (651)

.06b

Bortezomib use in 1 y after diagnosis (%, n)

31.2 (102)

33.5 (1379)

.40 b

47.0 (87)

48.6 (1289)

.68b

Mean number of therapies in first regimen (mean)
Treatment with ≥3 therapies in first regimen (%, n)

2.1
22.3 (73)

b

3.3

2.0

.01

a

2.2

.06b

18.1 (746)

.04a

2.0

25.9 (48)

.16b

21.5 (571)

Abbreviations: BMI, body mass index; CrCl, creatinine clearance; MM, multiple myeloma; VTE, venous thromboembolism.
a

t test.

b
c

Chi-square.

Cochran-Mantel-Haenszel (row mean score) test.

to those treated near 2006 as well as overweight (BMI > 25-30)

0.1

decreased mortality included first-line therapy with lenalidomide
or thalidomide and higher number of initial treatment therapies at
diagnosis.

4 | DISCUSSION
In this population-based cohort of 4446 patients with newly diagnosed MM starting therapy, VTE was associated with a 67% in-

Cumulative Incidence of VTE

or obesity (BMI > 30). Treatment characteristics associated with

0.08

0.06

0.04
Full cohort
0.02
July 2006 and after cohort

creased relative risk of mortality at 6 months. In patients treated
after FDA approval of lenalidomide in July 2006, development
of VTE was associated with a twofold increased risk of mortality
at 6 months, with risk persisting to 12 months after initiation of
therapy.
Prior literature shows conflicting results regarding the association
between VTE and mortality in MM. Studies assessing the impact of

0

0

1

2

3

4

5

6

7

8

9

10 11 12

Months since start of chemotherapy
F I G U R E 2 Cumulative incidence of VTE events over 1 y after
initiation of therapy for multiple myeloma in the full cohort and July
2006 and after cohort. VTE, venous thromboembolism
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TA B L E 2
myeloma

Characteristics of VTE in 4446 veterans with multiple

1207

thrombosis. This creates confounding, as VTE in observational studies
or retrospective analyses of clinical trials may be a marker of highly effective therapy. Therefore, adjustment for the presence of confound-

Characteristics of venous thromboembolism n = 327

ers that increase risk of VTE and also improve mortality is critical in

Type and location of VTE

n

Pulmonary embolism

50

from clinical trials is questionable, as selection criteria for trials result

Pulmonary embolism and lower-extremity deep vein
thrombosis

42

in enrollment of patients with better prognoses and reduced comor-

any observational study. Additionally, the generalizability of outcomes

bidities compared to most patients with cancer in routine practice and

Lower-extremity deep vein thrombosis

only 5% of cancer patients participate in clinical trials.23,24 Our study

Distal

17

supports other population-based studies that identify an association

Proximal

158

with between VTE and mortality.7

Site not specified

14

This study has several limitations. We were unable to examine
rate of VTE-related death and cause-specific mortality due to limita-

Upper-extremity deep vein thrombosis
Line associated

20

tions in determination of death in nationwide VHA data. Additionally,

Not line associated

13

our analysis likely underestimates the effect of VTE on mortality, as

Deep vein thrombosis, site not specified

13

all patients had to survive long enough to receive therapy with adequate performance status for treatment. The generalizability of our

VTE on survival in clinical trials found no association between VTE

findings to women may be limited because our population was 98%

in mortality.6,22 However, modern therapies that have improved out-

male. Also, because of the retrospective analysis of existing data,

comes (such as lenalidomide and HCT) are also associated with risk of

causality of adverse outcomes could not be determined and result

TA B L E 3 Association between VTE
and mortality in US veterans diagnosed
with MM between September 1, 1999 and
June 30, 2014

6-mo mortality

12-mo mortality

HR

95% CI

P value

HR

95% CI

P value

VTE (time varying)

1.63

1.18-2.37

<.001

1.22

0.93-1.60

.16

Year of diagnosis

1.00

0.98-1.03

.84

1.00

0.98-1.02

.74

1.28-2.52

<.001

1.53

1.14-2.06

.01

BMI
< 18.5

1.79

18.5-25

Referent

25-30

0.81

0.69-0.96

.01

0.79

0.69-0.90

<.001

≥ 30

0.72

0.60-0.87

<.001

0.74

0.64-0.86

<.001

Age (per y)

1.01

1.00-1.02

.03

1.01

1.00-1.01

.02

Referent

Race
Non-Black

Referent

Black

0.78

0.67-0.92

<.001

0.74

0.65-0.84

<.001

1.08

1.06-1.11

<.001

1.07

1.05-1.09

<.001

Hemoglobin < 10 g/
dL

1.15

0.99-1.33

.06

1.17

1.04-1.32

.01

CrCl < 30 mL/min

1.48

1.26-1.73

<.001

1.31

1.15-1.50

<.001

Albumin ≤ 3 g/dL

1.70

1.47-1.98

<.001

1.60

1.42-1.81

<.001

Albumin unknown

0.70

0.54-0.91

.01

0.70

0.57-0.86

<.001

Charlson Comorbidity
Index, per point

Referent

Baseline laboratory data

Myeloma-specific therapy
Transplant

NE

0.03-0.14

<.001

Thalidomide

0.66

0.55-0.79

.11

0.66

0.58-0.76

<.001

Bortezomib

0.85

0.69-1.04

<.001

0.82

0.70-0.96

.01

Lenalidomide

0.42

0.32-0.55

.06

0.45

0.38-0.55

<.001

0.71

0.61-0.82

<.001

0.71

0.61-0.82

<.001

Number of therapies in
first regimen

<.001
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6-mo mortality

12-mo mortality

HR

95% CI

P value

HR

95% CI

P value

VTE (time varying)

2.37

1.56-3.60

<.001

1.69

1.21-2.36

<.001

Year of diagnosis

0.94

0.89-0.98

.01

0.95

0.92-0.99

.02

< 18.5

1.70

1.10-2.63

.02

1.49

1.01-2.21

.05

18.5-25

Referent

TA B L E 4 Association between VTE
and mortality in US veterans diagnosed
with MM between July 1, 2006, and June
30, 2014

BMI
Referent

25-30

0.75

0.61-0.93

.01

0.74

0.62-0.89

.001

≥ 30

0.72

0.57-0.92

.01

0.78

0.64-0.94

.01

1.01

1.00-1.02

.03

1.01

1.00-1.02

.07

Age (per y increase)
Race
Non-Black

Referent

Black

0.84

0.69-1.02

.08

0.75

0.64-0.89

<.001

1.07

1.04-1.10

<.001

1.07

1.04-1.09

<.001

Hemoglobin < 10 g/
dL

1.17

0.97-1.41

.11

1.15

0.99-1.35

.07

CrCl < 30 mL/min

1.50

1.23-1.83

<.001

1.30

1.09-1.54

<.001

Charlson Comorbidity
Index, per point

Referent

Baseline laboratory data

Albumin ≤ 3 g/dL

1.70

1.41-2.05

<.001

1.60

1.36-1.87

<.001

Albumin unknown

0.59

0.39-0.89

.01

0.60

0.43-0.82

<.001

0.05

0.02-0.16

<.001

Myeloma-specific therapy
Transplant

NE

Thalidomide

0.49

0.37-0.63

<.001

0.52

0.42-0.64

<.001

Bortezomib

0.91

0.73-1.14

.42

0.88

0.74-1.05

.16

Lenalidomide

0.43

0.32-0.57

<.001

0.46

0.38-0.56

<.001

0.71

0.59-0.84

<.001

0.84

0.73-0.97

.01

Number of therapies in
first regimen

may be affected by unmeasured confounders. Despite these limita-

overdiagnosis of adverse events that can occur based on ICD-9

tions, the equal access to diagnostics and treatment, high rates of

codes alone. In our cohort, 81.5% of patients were treated with two

comorbidities, and integrated health data systems of the VHA allow

or fewer therapies within 6 months of diagnosis, which may have

for a robust analysis of patient characteristics, treatments, and VTE

resulted in the decreased incidence of VTE.
This study found that VTE events during the first 6 months

that is generally not possible in other retrospective studies.
This study has several strengths. We also included a measure of

of therapy are associated with increased mortality. Recently, two

comorbidities and analyzed outcomes while adjusting for common

large studies found that direct oral anticoagulants are safe and

treatments to help disentangle the thrombogenic effect of treatments,

effective in prevention of VTE in patients with cancer when ad-

such as lenalidomide, or HCT. Patients in this study had a median age of

ministered during the first 6 months of therapy.11,12 In these trials,

68 years, which is similar to the median age of patients in Surveillance,

patients were identified as high risk for VTE based on a Khorana

Epidemiology, and End Results data of 69 years. In comparison to other

risk score ≥ 2, 26 which includes factors including site of cancer,

observational cohorts of MM and VTE, patients in our study were

platelet count, hemoglobin, leukocyte count, and elevated BMI. 26

slightly younger (68 years) than those in the Swedish study (71 years),7

While these studies contained < 3% of participants with my-

25

and included more Blacks, who tend to develop MM at a younger age.

eloma, a similar practice may be effective in preventing VTE in

Our cohort was older than those in clinical trials of combination chemo-

MM. Recent work to define risk of VTE in patients with MM start-

therapy (57 years)5 and immunomodulatory agents (63 years)6 for MM.

ing chemotherapy, such as the IMPEDE-VTE or SAVED score,15,16

Additionally, we used a previously validated method of throm-

could help to determine which patients are at highest risk for VTE

19

bosis identification

that incorporates both diagnostic codes and

treatment to identify VTE in conjunction with manual abstraction

to facilitate prospective study of the benefits of thromboprophylaxis in MM.

to verify events. This two-factor identification allows for detection

In conclusion, VTE is associated with increased mortality at 6

of VTE with high specificity across large populations and prevents

months after initiation of therapy in patients with MM and at both 6
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and 12 months in a cohort of patients treated after July 2006, when
lenalidomide was approved. With the availability of safe and effective anticoagulants, a strategy for thromboprophylaxis in patients

6.

with MM at high-risk for VTE may improve survival.
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